Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986

Intraoperative Gamma Probes · CdTe + CsI(Tl) Family — what the literature says.

Six real anchor citations across the two intraoperative-gamma-probe detector families (CdTe / CdZnTe semiconductor and CsI(Tl) scintillator + APD) and the six surgical workflows they are bought for — sentinel-lymph-node biopsy (breast, melanoma, gynaecological, ENT, urological), radio-occult-lesion localisation (ROLL), parathyroid + recurrent thyroid revision surgery, and the honest boundary where ICG NIR fluorescence-guided surgery is a real alternative (surface-exposed nodes, sub-2-cm depth) vs where gamma-probe remains essential (deep nodes, revision surgery, obese patients). Every DOI + journal reference verified.

3 500 cps/MBqNEMA NU3-2004 sensitivity benchmark at 30 mm in air (Radnia 2021)
1 – 2 cmICG NIR fluorescence depth ceiling — where gamma-probe stays essential (Wölffer 2024)
48 / 48combined gamma + NIR SLN localisation vs blue-dye 42 / 48 (Schaafsma 2013)
Product specsEuroprobe 3.2 evidence
Filter
NEMA NU3-2004 characterisation — Radnia 2021
3 500
cps/MBq at 30 mm (air)
3 050
cps/MBq at 30 mm (scatter)
99.91 %
side / back shielding
NEMA NU3-2004 is the international acceptance standard for intraoperative-gamma-probe performance. Every serious clinical evaluation reports against these metrics — sensitivity, spatial resolution, angular response, energy resolution and shielding. Radnia 2021 is the modern reference cohort.
Detector characterisation2021
3 500 cps/MBqReference NEMA NU3-2004 sensitivity at 30 mm in air (3 050 cps/MBq in scattering tissue). 12 % energy window and 99.91 % side / back shielding define the benchmark the CdTe and CsI(Tl) probe families are engineered against for clean sentinel-node localisation

Development and characterization of an all-in-one gamma probe with auto-peak detection for sentinel lymph node biopsy based on NEMA NU3-2004 standard

Annals of Nuclear Medicine 35(4):438 – 446 — Radnia, Abdollahzadeh, Teimourian, Farahani, Akbari, Zaidi, Ay

CdTe / CdZnTe vs CsI(Tl) intraoperative probes
28.6 ± 0.7 mm
CdTe / CdZnTe (semiconductor)
sharper spatial resolution + energy resolution 17 keV FWHM (Tc-99m); compact geometry for laparoscopic work
vs
33.7 ± 0.8 mm
CsI(Tl) + APD (scintillator)
higher raw sensitivity above 140 keV; workhorse for deep-node sentinel-lymph-node localisation
CdTe vs CsI(Tl) trade-off2005
CdTe > CsI on resolution · CsI > CdTe on sensitivityDirect probe-vs-probe comparison in cervical + vulvar cancer sentinel-node localisation — CdZnTe spatial resolution 28.6 ± 0.7 mm vs CsI 33.7 ± 0.8 mm; CdZnTe energy resolution 17 keV FWHM at Tc-99m; CsI(Tl) + APD probe raw sensitivity higher at ≥ 140 keV

Evaluation of surgical gamma probes for sentinel node localization in cervical and vulvar cancer

Nuclear Medicine Review 8(2):83 – 87 (open access) — Wydra, Emerich, Sawicki et al.

Breast SLNB · gamma-probe vs ICG NIR — Gâta 2025
3.23 nodes
Tc-99m gamma probe (n = 286)
radiotracer localisation; standard-of-care with 99mTc nanocolloid + gamma probe
vs
3.20 nodes
ICG NIR fluorescence (n = 190)
visual green fluorescence; simpler workflow; sub-2-cm depth limitation
Breast SLNB · gamma vs ICG2025
p = 0.860476 breast-cancer SLNB patients (286 Tc-99m gamma-probe vs 190 ICG NIR fluorescence). Comparable nodes excised (3.23 vs 3.20; p = 0.860) and comparable positive-node capture. Both modalities give accurate axillary staging — the choice is workflow, not oncology

From gamma rays to green light — comparative efficacy of indocyanine green and technetium-99m in sentinel lymph node biopsy for breast cancer

Medical Sciences (Basel) 13(4):231 — Gâta, Ilieș, Antone, Pintican, Nistor-Ciurba, Țîțu, Orădan, Muntean, Filip, Irimie, Achimaș-Cadariu

ICG NIR fluorescence · Wölffer 2024 meta-analysis
1 – 2 cm
tissue-penetration depth ceiling
13 %
meta-FNR — ICG
10 %
meta-FNR — Tc-99m gamma probe
For melanoma SLNB, ICG NIR is a non-inferior alternative to gamma-probe once the surgical site is exposed — but the physics ceiling on skin-through-fat penetration is real. Deep-node cases + obese patients still favour gamma-probe localisation.
Melanoma · ICG depth limit2024
1 – 2 cmICG NIR fluorescence penetration depth reported at 1 – 2 cm across the meta-analysis. Transcutaneous detection rate varies from 21 % to 79 % depending on tissue thickness. Meta-FNR 13 % ICG vs 10 % Tc — non-inferior, but only after skin-through-fat penetration is manageable

Sentinel lymph node detection in cutaneous melanoma using indocyanine-green-based near-infrared fluorescence imaging — a systematic review and meta-analysis

Cancers (Basel) 16(14):2523 — Wölffer, Liechti, Constantinescu, Lese, Zubler

Combined vs single-modality SLNB — Schaafsma 2013
48 / 48 SLNs
Gamma + NIR (hybrid tracer)
100 % preoperative + intraoperative identification
vs
42 / 48 SLNs
Blue-dye alone
6 nodes missed vs the combined-modality reference standard
Combined gamma + NIR2013
48 / 48Combined gamma-probe + ICG-99mTc-nanocolloid hybrid tracer localised every axillary SLN (48 / 48) across 32 breast-cancer patients — while blue-dye alone missed 6 nodes. The combined-modality approach is the modern standard where both technologies are available

Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer

British Journal of Surgery 100(8):1037 – 1044 — Schaafsma, Verbeek, Rietbergen, van der Hiel, van der Vorst, Liefers, Frangioni, van de Velde, van Leeuwen, Vahrmeijer

Gamma probe L / BG — Gültekin 2013
3.66 ± 0.48
Pre-excision (lesion visible)
clear separation from surrounding tissue
vs
1.40 ± 0.27
Post-excision (residual bed)
confirmed complete removal — no residual on 8-month imaging
Recurrent thyroid + revision2013
3.66 → 1.40Gamma-probe lesion-to-background ratio dropped from 3.66 ± 0.48 pre-excision to 1.40 ± 0.27 post-excision — clean confirmation of complete lesion removal in a re-operated fibrotic surgical bed where visualisation alone would have missed residual disease

The contributions of gamma probe to lesion detectability and surgical safety in recurrent thyroid cancer at risk

Molecular Imaging and Radionuclide Therapy 22(2) — Gültekin, Saylam, Delibaşı, Korkmaz

Back to Onco Surgery knowledge hub

White Papers & Background Reading

FILE

NEMA NU3-2004 — Performance Measurements and Quality Control Guidelines for Non-Imaging Intraoperative Gamma Probes

International acceptance standard governing sensitivity, spatial resolution, angular response, energy resolution and shielding characterisation for intraoperative gamma probes — the benchmark every serious probe evaluation reports against.

Reference · NEMADownload
FILE

EANM / SNMMI — Practice Guidelines for Radionuclide-Guided Sentinel Node Biopsy

European (EANM) + North American (SNMMI) joint practice framework for radionuclide-guided sentinel-lymph-node biopsy across breast, melanoma, gynaecological and other cancers. Anchors the gamma-probe's role in the surgical decision.

Reference · EANM / SNMMIDownload
FILE

IAEA Practical Guidance on Peaceful Uses of Nuclear Technology in Health — Radioguided Surgery

IAEA framework for radioguided surgery programmes — probe QC, dose management, staff dose (extremity + whole-body), operating-theatre licence categories.

Reference · IAEADownload
FILE

AERB — Radioactive Material for Medical Application (India)

Indian regulatory framework governing intraoperative-radioguided-surgery use of Tc-99m nanocolloid + gamma-probe programmes; operating-theatre licence + extremity-dose monitoring requirements.

Reference · AERBDownload

Literature Radar · auto-updated daily

Latest radioguided-surgery research

Fresh peer-reviewed papers on intraoperative gamma probes, sentinel-lymph-node biopsy across breast / melanoma / gynae / uro / ENT / thyroid, radio-occult-lesion localisation and the hybrid gamma + fluorescence workflow. Auto-updated from Europe PMC.

See all in radar →
Loading recent papers…
Get the weekly digest →